Table 4.

Associations of TCF7L2 polymorphisms with breast cancer risk, by ER/PR status, The Breast Cancer Health Disparities Study

TCF7L2	Controls N = 3,215 Genotypes/copies	ER+/PR+ N = 1,265 cases OR (95 % CI)	ER+/PR− N = 229 cases OR (95 % CI)	ER−/PR+ N = 42 cases OR (95 % CI)	ER−/PR− N = 401 cases OR (95 % CI)
rs3750804	CC	1.00	1.00	1.00	1.00
	CT/TT	1.11 (0.97–1.26)	1.02 (0.77–1.34)	0.95 (0.51–1.77)	1.25 (1.01–1.54)
rs3814570	CC	1.00	1.00	1.00	1.00
	CT	1.15 (1.00–1.32)	1.07 (0.80–1.41)	0.68 (0.35–1.34)	1.08 (0.86–1.34)
	TT	1.00 (0.77–1.30)	1.23 (0.75–2.01)	0.83 (0.25–2.78)	1.49 (1.04–2.14)
rs4918796	TT	1.00	1.00	1.00	1.00
	TC	1.12 (0.97–1.29)	1.08 (0.81–1.45)	1.09 (0.54–2.21)	1.00 (0.80–1.26)
	CC	1.62 (1.20–2.20)	0.96 (0.46–2.02)	4.78 (1.89–12.12)	0.81 (0.44–1.50)
rs7900150	TT	1.00	1.00	1.00	1.00
	TA	1.06 (0.91–1.23)	1.10 (0.80–1.50)	1.06 (0.52–2.13)	1.08 (0.85–1.38)
	AA	1.19 (0.98–1.44)	1.43 (0.97–2.11)	1.31 (0.53–3.20)	1.59 (1.18–2.14)
rs7903146	CC	1.00	1.00	1.00	1.00
	CT	1.11 (0.97–1.28)	1.27 (0.96–1.69)	1.06 (0.54–2.07)	1.10 (0.88–1.38)
	TT	1.25 (0.98–1.61)	1.08 (0.63–1.87)	2.00 (0.74–5.43)	1.56 (1.07–2.27)
rs10749127	TT	1.00	1.00	1.00	1.00
	TC/CC	0.88 (0.77–1.00)	0.83 (0.64–1.09)	1.75 (0.93–3.31)	1.25 (1.02–1.55)
Haplotype
rs7081062
rs7903146
rs7900150
A-T-A	0	1.00	1.00	1.00	1.00
	1	1.10 (0.84–1.44)	1.71 (1.07–2.73)	1.36 (0.41–4.52)	1.26 (0.83–1.91)
	2	1.30 (1.00–1.68)	1.09 (0.62–1.92)	1.90 (0.66–5.44)	1.50 (1.01–2.24)
T-A-G	0	1.00	1.00	1.00	1.00
	1 + 2	1.07 (0.60–1.92)	2.91 (1.33–6.36)	too few	2.39 (1.20–4.75)

OR (odds ratios) and 95 % confidence interval (CI) adjusted for age, study, BMI in referent year, and genetic admixture ER/PR data are compared to 3,215 controls from the 4-CBCS and SFBCS with available data on ER/PR status